Antibody Therapy for Solid Tumors
Over the last several years the use of monoclonal antibody (MAb) therapy for the treatment of human malignancy has advanced from experimental therapy to standard of care for some malignancies. The success of MAb therapy stems not only from the ability to humanize the antibody, thus, decreasing the inherent immunogenicity of the approach but also from targeting appropriate proteins. Human cancers associated with the overexpression of particular growth factor receptors such as HER-2/neu, epidermal growth factor receptor, and vascular endothelial growth factor, have been impacted by commercially available antibodies. This review focuses on the mechanisms of action and clinical benefit of MAb therapy against common growth factor receptors.
Key WordsMonoclonal antibody EGFR HER-2/neu VEGF growth factor receptors
Unable to display preview. Download preview PDF.
- 13.Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neureceptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523–1530.PubMedGoogle Scholar
- 28.Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639–2648.PubMedGoogle Scholar
- 33.Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889–2895.PubMedCrossRefGoogle Scholar
- 41.Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptors. Proc Am Soc Clin Oncol 2001; 20:3a.Google Scholar
- 42.Saltz L, Meropol NJ, Loehrer PJ, Waksal H, Needle MN, Mayer RJ. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:127a.Google Scholar
- 44.Gatzemeieer U, Rosell R, Ramlau R, et al. Cetuximab (c225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor positive advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:642.Google Scholar
- 45.Kim ES, Mauer Am, Tran HT, et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:642.Google Scholar
- 47.Tabernero J, Rojo F, Jimenez E, et al. A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22:192.Google Scholar
- 56.Chen HX. Expanding the clinical development of bevacizumab. Oncologist 2003; 9(Suppl 1):27–35.Google Scholar